Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010)

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Zeitschrift für Rheumatologie (Print)

• Publication date

  2010-05-23

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00393-010-0612-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

  2009cited by this paper
• Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA).

  2009cited by this paper
• Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

  2009cited by this paper
• Empfehlungen zur Therapie mit Interleukin-1β-blockierenden Wirkstoffen

  2009cited by this paper
• IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

  2008cited by this paper
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Inhibiting interleukin-6 in rheumatoid arthritis

  2008cited by this paper
• Interleukin-6: discovery of a pleiotropic cytokine

  2006cited by this paper
• Interleukin-6 and rheumatic diseases

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• Humanized anti-interleukin-6 receptor antibody

  2005cited by this paper
• Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?

  2005cited by this paper
• Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.

  2005cited by this paper
• Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

  2005cited by this paper
• A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

  2004cited by this paper
• Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.

  2003cited by this paper
• Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.

  1997cited by this paper
• Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation

  1996cited by this paper
• Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.

  1993cited by this paper
• Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.

  1991cited by this paper
• Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

  1989cited by this paper
• The biology of interleukin-6.

  1989cited by this paper

• Effects of Concomitant Conventional and Previous Biological Disease Modifying Anti-Rheumatic Drugs Treatment on the Efficacy of Tocilizumab to Induce Remission in Patients with Rheumatoid Arthritis An Observational Real-Life Study

  2015cites this paper
• Tocilizumab for the treatment of rheumatoid arthritis

  2010cites this paper
• Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis

  2010cites this paper